Prognostic marker Musashi-2 modulates DNA damage response and radioresistance in diffuse large B-cell lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Treatment resistance is a significant challenge in diffuse large B-cell lymphoma (DLBCL) therapy.
• Musashi (MSI) RNA-binding proteins regulate gene expression and are implicated in tumorigenesis and treatment failure in other cancers.

Purpose of the Study:

• To investigate the role of MSI family proteins, specifically MSI1 and MSI2, in DLBCL treatment efficacy and resistance.
• To determine the prognostic relevance of MSI2 in DLBCL patients.

Main Methods:

• Analysis of publicly available gene expression data to assess MSI1 and MSI2 expression and prognostic value in DLBCL.
• Characterization of MSI2 co-expression networks.
• MSI2 knockdown experiments in DLBCL cells using qPCR, Western blot, protein arrays, and flow cytometry.
• Assessment of cell viability and clonogenic survival following radiotherapy and chemotherapy (vincristine, doxorubicin).

Main Results:

• MSI2 was significantly overexpressed in DLBCL and associated with unfavorable prognosis.
• High MSI2 expression correlated with increased stemness and DNA repair signaling.
• MSI2 knockdown reduced stemness markers, impaired DNA repair, and increased sensitivity to radiation, vincristine, and doxorubicin.

Conclusions:

• MSI2 acts as a prognostic marker in DLBCL and influences sensitivity to genotoxic therapies.
• Targeting MSI2 may enhance the efficacy of DNA-targeted treatments for DLBCL.